TY - JOUR
T1 - Botulinum toxin A and B
T2 - A comparative dosing study for spasmodic dysphonia
AU - Blitzer, Andrew
N1 - Funding Information:
Thirty-two patients with adductor spasmodic dysphonia (ADSD) who had stable doses and results were offered Botulinum toxin B (BTX-B: Myobloc from Elan Pharmaceuticals, Inc., San Francisco, CA, USA). The inclusion criteria were outpatient males or females who were English speaking, of any race, who have adductor spasmodic dysphonia. They must have been treated at the New York Center for Voice and Swallowing Disorders successfully for at least 1 year with Botox. The exclusion criteria included pregnant or lactating females; subjects with known allergic reactions to Botulinum toxin; patients with myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, myopathy, or any disease that might interfere with neuromuscular function; subjects with severe systemic disease; subjects using aminoglycoside antibiotics; or subjects who have a medical condition which might put the subject at risk may confound the study results, or interfere with the subjects' participation in the study. This study was supported by an unrestricted research grant from Elan, Inc. The study was reviewed and monitored by the Western IRB in Seattle.
PY - 2005/12
Y1 - 2005/12
N2 - OBJECTIVE: The purpose of this study was to find the conversion factor, safety, and efficacy of type A to type B toxin for laryngeal muscles. METHODS: Thirty-two patients with adductor spasmodic dysphonia with stable doses of A toxin to manage their symptom were given type B toxin starting at a conversion of 1 U of BTX-A to 50 U of BTX-B. The patients were followed for 1 year, and doses adjusted according to response. RESULTS: The conversion factor was found to be 52.3 U : 1 U. The onset of action of type B was more rapid (2.09 days vs 3.2 days [P = 0.028]), with a shorter duration of benefit (10.8 weeks vs 17 weeks [P = 0.002). The safety profile for A and B toxin appeared the same, with 3 patients receiving Myobloc reporting dry mouth. CONCLUSION: This study shows that a conversion factor of 52.3:1 Myobloc (BTX-B) to Botox (BTX-A) and that Myobloc is an effective alternative to Botox (BTX-A) for patients with spasmodic dysphonia. EBM RATING: B-2
AB - OBJECTIVE: The purpose of this study was to find the conversion factor, safety, and efficacy of type A to type B toxin for laryngeal muscles. METHODS: Thirty-two patients with adductor spasmodic dysphonia with stable doses of A toxin to manage their symptom were given type B toxin starting at a conversion of 1 U of BTX-A to 50 U of BTX-B. The patients were followed for 1 year, and doses adjusted according to response. RESULTS: The conversion factor was found to be 52.3 U : 1 U. The onset of action of type B was more rapid (2.09 days vs 3.2 days [P = 0.028]), with a shorter duration of benefit (10.8 weeks vs 17 weeks [P = 0.002). The safety profile for A and B toxin appeared the same, with 3 patients receiving Myobloc reporting dry mouth. CONCLUSION: This study shows that a conversion factor of 52.3:1 Myobloc (BTX-B) to Botox (BTX-A) and that Myobloc is an effective alternative to Botox (BTX-A) for patients with spasmodic dysphonia. EBM RATING: B-2
UR - https://www.scopus.com/pages/publications/29144502347
U2 - 10.1016/j.otohns.2005.09.008
DO - 10.1016/j.otohns.2005.09.008
M3 - Article
C2 - 16360499
AN - SCOPUS:29144502347
SN - 0194-5998
VL - 133
SP - 836
EP - 838
JO - Otolaryngology - Head and Neck Surgery
JF - Otolaryngology - Head and Neck Surgery
IS - 6
ER -